WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013125891) MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/125891    International Application No.:    PCT/KR2013/001417
Publication Date: 29.08.2013 International Filing Date: 22.02.2013
IPC:
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61K 47/42 (2006.01), A61K 47/48 (2006.01)
Applicants: ALTEOGEN INC. [KR/KR]; #305, 1662 Yuseong-daero Yuseong-gu Daejeon 305-811 (KR)
Inventors: PARK, Soon Jae; (KR).
CHUNG, Hye-Shin; (KR).
KWON, Seonhun; (KR).
LEE, Sunbae; (KR).
YOU, Sun-Ah; (KR).
KIM, Yong Mo; (KR)
Agent: LEE, Cheo Young; 11th, Yeosam Bldg. 648-23, Yeoksam-dong Gangnam-gu Seoul 135-080 (KR)
Priority Data:
10-2012-0019221 24.02.2012 KR
Title (EN) MODIFIED ANTIBODY IN WHICH MOTIF COMPRISING CYSTEINE RESIDUE IS BOUND, MODIFIED ANTIBODY-DRUG CONJUGATE COMPRISING THE MODIFIED ANTIBODY, AND PRODUCTION METHOD FOR SAME
(FR) ANTICORPS MODIFIÉ DANS LEQUEL UN MOTIF COMPORTANT UN RÉSIDU CYSTÉINE EST LIÉ, CONJUGUÉ ANTICORPS MODIFIÉ-MÉDICAMENT COMPORTANT L'ANTICORPS MODIFIÉ, ET SON PROCÉDÉ DE FABRICATION
(KO) 시스테인 잔기를 포함하는 모티프가 결합된 변형항체, 상기 변형항체를 포함하는 변형항체-약물 접합체 및 그 제조방법
Abstract: front page image
(EN)The present invention concerns: an antibody in which a motif consisting of a peptide or an amino acid comprising one or more cysteine residues is bound to a terminal and more particularly a medium-chain terminal of the parent antibody; a modified antibody-drug conjugate (mADC, antibody-drug conjugate) in which the antibody and a drug are bound; and a production method for the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate (mADC, antibody-drug conjugate) according to the present invention is highly specific to antigens of the antibody comprised in the conjugate and so can accurately deliver the drug to target cells and hence can increase the therapeutic effect and can also bring about greater utilisation of drugs and particularly anticancer drugs and the like of which use is limited due to toxicity despite being highly effective. Also, the present invention concerns a composition for treating diseases and particularly cancer by using the modified antibody-drug conjugate.
(FR)La présente invention concerne : un anticorps dans lequel un motif, consistant en un peptide ou en un acide aminé comportant au moins un résidu cystéine, est lié à une extrémité terminale et, plus particulièrement, à une extrémité terminale de chaîne moyenne de l'anticorps parent ; un conjugué anticorps modifié-médicament (mDAC, conjugué anticorps-médicament) dans lequel l'anticorps et un médicament sont liés ; un procédé de fabrication de l'anticorps ou du conjugué anticorps modifié-médicament. Le conjugué anticorps modifié-médicament (mDAC, conjugué anticorps-médicament) selon la présente invention est fortement spécifique des antigènes de l'anticorps compris dans le conjugué et peut ainsi administrer de façon précise le médicament à des cellules cibles et, par conséquent, peut augmenter l'effet thérapeutique et peut également fournir une meilleure utilisation des médicaments et, en particulier, des médicaments anticancéreux et autres dont l'utilisation est limitée en raison de la toxicité malgré leur efficacité élevée. La présente invention concerne également une composition pour le traitement de maladies et, en particulier, du cancer par l'utilisation du conjugué anticorps modifié-médicament.
(KO)본 발명은 하나 이상의 시스테인 잔기를 포함한 아미노산 또는 펩티드로 이루어진 모티프(motif)가 모항체의 말단, 특히 중쇄 말단에 결합된 항체, 그러한 항체와 약물이 결합된 변형항체-약물 접합체(mADC, Antibody-Drug Conjugate) 및 상기 항체 또는 변형항체-약물 접합체의 제조방법에 대한 것이다. 본 발명에 따른 변형항체-약물 접합체(mADC, Antibody-Drug Conjugate)는 접합체에 포함된 항체의 항원에 대한 높은 특이성으로 인해 타겟 세포에 약물을 정확하게 전달할 수 있어, 치료효과를 높일 수 있으며, 또한 높은 효과에도 불구하고 독성으로 인해 사용이 제한적인 약물, 특히 항암제 등의 활용도를 제고할 수 있다. 또한, 본 발명은 상기 변형항체-약물 접합체를 이용한 질병, 특히 암의 치료용 조성물에 대한 것이다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)